Review Article
Systematic Review of Compound Danshen Dropping Pill: A Chinese Patent Medicine for Acute Myocardial Infarction
Table 7
Analyses of secondary outcomes.
| Outcomes (comparisons) | Treatment | Control | Weight (%) | MD | 95% CI | Mean | SD | | Mean | SD | |
| (4) LVEF% | | | | | | | | | |
(4.1) CDDP + conventional therapy versus conventional therapy | Mei et al. 2006 [34] | 60.80 | 7.20 | 23 | 59.20 | 6.80 | 22 | 10.50 | 1.60 | 2.49, 5.69 | Xu and Wang 2007 [21] | 51.20 | 4.30 | 66 | 47.10 | 4.60 | 80 | 34.60 | 4.10 | 2.65, 5.55 | Li et al. 2011 [19] | 57.10 | 8.70 | 252 | 51.90 | 9.90 | 248 | 31.70 | 5.20 | 3.57, 6.83 | Lin 2011 [33] | 54.50 | 6.80 | 46 | 47.80 | 3.90 | 44 | 23.30 | 6.70 | 4.42, 8.98 |
| Total (REM, = 51%) | | | | | | | 100.00 | 4.79 |
[3.31, 6.28]
|
| Subgroup analysis (according to duration of treatment) | | | | | | | | | | (4.1.1) 30 days–6 weeks | | | | | | | | | | Li et al. 2011 [19] | 57.10 | 8.70 | 252 | 51.90 | 9.90 | 248 | 33.90 | 5.20 | 3.57, 6.83 | Lin 2011 [33] | 54.50 | 6.80 | 46 | 47.80 | 3.90 | 44 | 17.40 | 6.70 | 4.42, 8.98 |
| Subtotal (FEM, = 9%) | | | | | | | 51.30 | 5.71 |
[4.38, 7.04]
|
| (4.1.2) 6 months–12 months | | | | | | | | | | Mei et al. 2006 [34] | 60.80 | 7.20 | 23 | 59.20 | 6.80 | 22 | 5.40 | 1.60 | 2.49, 5.69] | Xu and Wang 2007 [21] | 51.20 | 4.30 | 66 | 47.10 | 4.60 | 80 | 43.30 | 4.10 | 2.65, 5.55 |
| Subtotal (FEM, = 22%) | | | | | | | 48.70 | 3.82 |
[2.46, 5.19]
|
|
(4.2) CDDP + conventional therapy versus placebo + conventional therapy | Li et al. 2010 [36] | 55.69 | 9.34 | 42 | 50.21 | 7.83 | 21 | 100.00 | 5.48 | 1.10, 9.86 |
(4.3) CDDP + conventional therapy versus propranolol + conventional therapy | Xu and Wang 2007 [21] | 51.20 | 4.30 | 66 | 49.60 | 5.00 | 72 | 100.00 | 1.60 | 0.05, 3.15 | (5) Quality of life (score) | | | | | | | | | |
CDDP + conventional therapy versus placebo + conventional therapy | Li et al. 2010 [36] | 110.28 | 19.33 | 42 | 97.68 | 17.13 | 21 | 100.00 | 12.60 | 3.23, 21.97 |
|
|